Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study

被引:1
|
作者
Nalwanga, Damalie [1 ,2 ]
Musiime, Victor [1 ,3 ]
Bangirana, Paul [4 ]
Nishiguchi, Erika Phelps [5 ]
Kiggwe, Andrew [2 ]
Ssesanga, Titus [3 ]
Ssenkusu, John M. [6 ]
Musoke, Philippa [1 ]
Cusick, Sarah E. [7 ]
机构
[1] Makerere Univ, Sch Med, Dept Paediat & Child Hlth, Coll Hlth Sci, POB 7072, Kampala, Uganda
[2] Makerere Univ Lung Inst, POB 7749, Kampala, Uganda
[3] Joint Clin Res Ctr, Res Dept, POB 10005, Kampala, Uganda
[4] Makerere Univ, Sch Med, Dept Psychiat, Coll Hlth Sci, POB 7072, Kampala, Uganda
[5] Univ Washington, Dept Paediat, Div Dev Behav Paediat, Seattle, WA 98195 USA
[6] Makerere Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Coll Hlth Sci, POB 7072, Kampala, Uganda
[7] Univ Minnesota, Dept Paediat, Minneapolis, MN USA
基金
美国国家卫生研究院;
关键词
Neurocognitive function; Children; HIV; ART; NEUROPSYCHOLOGICAL PERFORMANCE; COGNITIVE IMPAIRMENT; NAIVE; DEFICITS; OUTCOMES; CARE; ART;
D O I
10.1186/s12887-021-02676-2
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background HIV infection is associated with significant neurocognitive deficits making maximization of cognitive function among children receiving antiretroviral therapy (ART) a public health imperative. Non-protease inhibitors (non-PIs) achieve higher drug levels in the cerebral spinal fluid (CSF) compared to PIs, potentially leading to better neurocognitive function by reducing CSF viral load and inflammation. ART that maximises children's neurodevelopment and school achievement could result in improved quality of life and productivity as adults, but little research to date has examined whether non-PI ART is associated with better neurocognitive outcomes. We compared the neurocognitive function between children living with HIV receiving PI-based and non PI-based ART. Methods We recruited a consecutive sample of clinically stable Ugandan children living with HIV aged 5-12 years who received PI-based or non PI-based ART for >= 1 year (viral load < 1000 copies). Neurocognitive function was assessed using the Kaufman Assessment Battery for Children, the Test of Variables of Attention, and Bruininks-Oseretsky Test of Motor Proficiency. Age-adjusted neurocognitive z-scores for the two groups were compared using linear regression models in STATA version 13. The Hommel's method was used to adjust for multiple testing. Results We enrolled 76 children living with HIV; 34 on PI ART and 42 on non-PI ART. Mean (+/- SD) age was greater in the non-PI vs. PI group (9.5 +/- 1.9 vs. 8.5 +/- 2.0) years (p = 0.03). Children in the non-PI group had lower socioeconomic scores (5.7 +/- 3.3 vs. 7.4 +/- 2.8, p = 0.02). There was no difference in neurocognitive function between the groups (adjusted p > 0.05) for KABC and TOVA. Children in the PI group had better total BOT scores than their counterparts (46.07 +/- 1.40) vs. 40.51 (1.24), p = 0.03). Conclusions We detected no difference in neurocognitive function among children on PI and non PI-based ART therapy based on KABC and TOVA tests. Children on PI based ART had better motor function than their counterparts. We recommend a prospective study with a larger sample size.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study
    Damalie Nalwanga
    Victor Musiime
    Paul Bangirana
    Erika Phelps Nishiguchi
    Andrew Kiggwe
    Titus Ssesanga
    John M. Ssenkusu
    Philippa Musoke
    Sarah E. Cusick
    BMC Pediatrics, 21
  • [2] Protease inhibitor therapy in HIV-infected children
    Feingold, AR
    Rutstein, RM
    Meislich, D
    Brown, T
    Rudy, BJ
    AIDS PATIENT CARE AND STDS, 2000, 14 (11) : 589 - 593
  • [3] Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy
    Suaysod, Rapeepan
    Ngo-Giang-Huong, Nicole
    Salvadori, Nicolas
    Cressey, Tim R.
    Kanjanavanit, Suparat
    Techakunakorn, Pornchai
    Krikajornkitti, Sawitree
    Srirojana, Sakulrat
    Laomanit, Laddawan
    Chalermpantmetagul, Suwalai
    Lallemant, Marc
    Le Coeur, Sophie
    McIntosh, Kenneth
    Traisathit, Patrinee
    Jourdain, Gonzague
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (01) : 95 - 101
  • [4] MALARIA IN HIV-INFECTED CHILDREN RECEIVING HIV PROTEASE-INHIBITOR-COMPARED WITH NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED ANTIRETROVIRAL THERAPY
    Hobbs, Charlotte V.
    Gabriel, Erin
    Kamthunzi, Portia
    Tegha, Gerald
    Petzold, Elizabeth Wills
    Barlow-Mosha, Linda
    Chi, Benjamin H.
    Li, Yonghua
    Ilmet, Tiina
    Kirmse, Brian
    Neal, Jillian
    Parikh, Sunil
    Deygoo, Nagamah
    Jean-Philippe, Patrick
    Mofenson, Lynne
    Prescott, William
    Musoke, Philippa
    Palumbo, Paul
    Duffy, Patrick E.
    Borkowsky, William
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 604 - 604
  • [5] Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children
    Abadi, J
    Sprecher, E
    Rosenberg, MG
    Dobroszycki, J
    Sansary, J
    Fennelly, G
    Wiznia, A
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (03) : 298 - 303
  • [6] Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients
    Salmon-Céron, D
    Deleuze, J
    Coste, J
    Guerin, C
    Ginsburg, C
    Blanche, P
    Finkielsztejn, L
    Pecqueux, L
    Chaput, S
    Gorin, I
    Sicard, D
    ANNALES DE MEDECINE INTERNE, 2000, 151 (04): : 297 - 302
  • [7] In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy
    Ananworanich, J
    Nuesch, R
    Teeratakulpisam, S
    Srasuebkul, P
    Chuenyam, T
    Siangphoe, U
    Ungsedhaphand, C
    Phanuphak, P
    Ruxrungtham, K
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (05) : 570 - 572
  • [8] Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens
    Visnegarwala, F
    Darcourt, J
    Sajja, P
    Menon, V
    Ong, O
    Maldonado, M
    White, AC
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (05) : 653 - 655
  • [9] Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy
    Calza, L
    Manfredi, R
    Farneti, B
    Chiodo, F
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (01) : 54 - 59
  • [10] No Differences of Immune Activation and Microbial Translocation Among HIV-infected Children Receiving Combined Antiretroviral Therapy or Protease Inhibitor Monotherapy
    Falcon-Neyra, Lola
    Benmarzouk-Hidalgo, Omar J.
    Madrid, Lola
    Noguera-Julian, Antoni
    Fortuny, Claudia
    Neth, Olaf
    Lopez-Cortes, Luis
    MEDICINE, 2015, 94 (11) : e521